TEVIY and Earnings Play: NCOG + 1 1/2. Earnings Play: NCO Group, Inc. Reports Net Income of $0.28 Per Share Before Non-Recurring Acquisition Costs and Preferred Stock Accretion
FORT WASHINGTON, Pa., May 13 /PRNewswire/ -- NCO Group, Inc. (''NCO'') (Nasdaq: NCOG - news), a leading provider of accounts receivable management and other outsourced services, reported today that strong growth and a focus on operating efficiencies boosted revenue and operating profits to record levels.
Analysts very positve about NCOG.>>
5/14/99 BT/Alex. Brown reiterates strong buy, reported 1Q 99 EPS of $0.28 vs. $0.20 last year, raising FY 99 estimate
5/14/99 Merrill Lynch reiterates 2-1 rating, 1Q results strong, co agrees to acquire Compass Intl, 1999 estimates $1.27
3/9/99 Merrill Lynch initiate coverage wit a 2-1 rating, target $40
3/2/99 Prudential reiterates strong buy, target $45, raised 1999 from $1.22 to $1.28, 2000 from $1.58 to $1.66
*******************
TEVIY
One of my favorite Israeli drug stocks is called TEVIY.. Its the Warner Lambert from Israel and very well respected company in Israel and all over Europe
Teva Pharmaceutical Industries Ltd. Receives Approval From the Swiss Intercantonal Medicines Control Office, the IKS, For Sale of Copaxone In Switzerland
-First Western European Approval for Copaxone(R) -
JERUSALEM, Israel--(BUSINESS WIRE)--May 11, 1999-- Teva Pharmaceutical Industries Ltd, (NASDAQ: TEVIY - news) announced today at its investor seminar and field trip in Hungary that the Swiss Intercantonal Medicines Control office, the IKS, has granted marketing clearance for Copaxone® for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). This is Copaxone®'s first Western European approval. With the addition of Switzerland, Copaxone® is now approved in 14 countries.
The approved Multiple Sclerosis therapeutic indication is for the reduction of frequency of relapses and decreasing the progression of disability. Copaxone(r) is the only MS-specific immunomodulator available today. |
